Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I multicenter, double-blind, single dose, dose-ranging study, in healthy men
to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of
Dimethandrolone Undecanoate (DMAU) administered as an intramuscular or subcutaneous
injection.
Phase:
Phase 1
Details
Lead Sponsor:
Health Decisions
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Los Angeles Biomedical Research Institute Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center University of Washington